Related Experiment Video

Updated: Sep 19, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K

The current and emerging immunotherapy paradigm in small-cell lung cancer

Kang Qin1, Carl M Gay1, Lauren A Byers2

  • 1Department of Thoracic/Head & Neck Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Nature Cancer
|June 5, 2025
PubMed

Insights

Small-cell lung cancer (SCLC) treatment has advanced with immunotherapy. Atezolizumab combined with chemotherapy offers a new standard of care, improving outcomes for extensive-stage SCLC patients.

Area of Science:

  • Oncology
  • Immunotherapy
  • Medical Research

Background:

  • Small-cell lung cancer (SCLC) is an aggressive cancer with historically poor prognosis.
  • Etoposide-platinum chemotherapy was the standard but often led to treatment resistance.
  • Recent advancements have introduced new therapeutic options for SCLC.

Purpose of the Study:

  • To review the current landscape of immunotherapies in SCLC treatment.
  • To discuss emerging therapeutic strategies for SCLC.
  • To emphasize the role of biomarkers in patient selection for SCLC therapies.

Main Methods:

  • Literature review of recent clinical trials and studies.
  • Analysis of treatment guidelines and FDA approvals.
  • Synthesis of data on immunotherapy efficacy and resistance mechanisms.

Main Results:

  • Atezolizumab, an anti-PD-L1 antibody, combined with etoposide-platinum is now a first-line standard for extensive-stage SCLC.
  • This combination therapy represents a significant paradigm shift in SCLC treatment.
  • Ongoing research focuses on overcoming resistance and identifying predictive biomarkers.

Conclusions:

  • Immunotherapy, particularly atezolizumab, has transformed SCLC treatment paradigms.
  • Further research into biomarkers is crucial for optimizing patient selection and treatment response.
  • The development of novel immunotherapeutic strategies holds promise for improving SCLC patient outcomes.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
522
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K